SUBSCRIBE: Print / eNewsletter
Prophylactic HPV vaccination significantly reduced vaccine-type oral HPV infections among young adults, according to the results of a cross-sectional study.
David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer
In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.
Vitamin A Derivative Does Not Prevent Second Primary Tumors in Head and Neck Cancer Patients
Chemoprevention with low-dose 13-Cis retinoic acid, a synthetic vitamin A derivative, did not lower the incidence of second primary tumors in patients with squamous cell cancer of the head and neck.
High-Intensity Local Treatment May Improve Head and Neck Cancer Survival
The addition of high-intensity primary tumor ablation in addition to systemic chemotherapy may improve the survival of patients with metastatic head and neck squamous cell carcinoma.
Adherence to Quality Metrics Could Improve Head and Neck Cancer Survival
Adherence to each of five quality metrics for head and neck squamous cell carcinoma was associated with a reduced risk for death.
Increased Node Dissection Improved Survival in Node-Negative Oral Cavity SCC
Higher nodal yield during definitive surgery for clinically node-negative oral cavity squamous cell carcinoma was associated with improved mortality.
Three-Weekly Cisplatin Superior to Weekly Dose in Head and Neck Cancer
Three-weekly cisplatin is superior to a weekly dose in preventing locoregional relapse when combined with radiotherapy in head and neck squamous cell carcinoma.
Nivolumab Maintained QOL in Advanced Squamous Cell Head and Neck Cancer
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with the checkpoint inhibitor nivolumab were able to maintain baseline levels of quality of life.
Chemo Prior to CRT in Nasopharyngeal Carcinoma May Improve Outcomes
The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma.
Role for Afatinib in p16-Negative Head and Neck Cancer?
This video reviews results of LUX-Head & Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer.
Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer
This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.